Silvia Velazquez-Garcia

Silvia Velazquez-Garcia

Auto-generated profile, based on publicly available information

Silvia Velazquez-Garcia

Universidad de La Laguna

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2006 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
EPEsteban Porrini
Esteban Porrini
PDPatricia Delgado
Patricia Delgado
CBCelia Bigo
Celia Bigo
AAAlejandra Alvarez
Alejandra Alvarez
MCMarian Cobo
Marian Cobo
ATArmando Torres
Armando Torres

21 January 2011 in Diabetes
Verified
Journal Article
Open access
PDF file
JMJose Mellado-Gil
Jose Mellado-Gil
TRTaylor C. Rosa
Taylor C. Rosa
CDCem Demirci
Cem Demirci
JGJose A. Gonzalez-Pertusa
Jose A. Gonzalez-Pertusa
SVSilvia Velazquez-Garcia
Silvia Velazquez-Garcia
AGAdolfo Garcia-Ocaña
Adolfo Garcia-Ocaña
OBJECTIVE: To determine the role of hepatocyte growth factor (HGF)/c-Met on β-cell survival in diabetogenic conditions in vivo and in response to cytokines in vitro. RESEARCH DESIGN AND METHODS: We generated pancreas-specific c-Met-null (PancMet KO) mice and characterized their response to diabetes induced by multiple low-dose streptozotocin (MLDS) administration. We also analyzed the effect of HGF/c-Met signaling in vitro on cytokine-induced β-cell death in mouse and human islets, specifically examining the role of nuclear factor (NF)-κB. RESULTS: Islets exposed in vitro to cytokines or from MLDS-treated mice displayed significantly increased HGF and c-Met levels, suggesting a potential role for HGF/c-Met in β-cell survival against diabetogenic agents. Adult PancMet KO mice displayed normal glucose and β-cell homeostasis, indicating that pancreatic c-Met loss is not detrimental for β-cell growth and function under basal conditions. However, PancMet KO mice were more susceptible to MLDS-induced diabetes. They displayed higher blood glucose levels, marked hypoinsulinemia, and reduced β-cell mass compared with wild-type littermates. PancMet KO mice showed enhanced intraislet infiltration, islet nitric oxide (NO) and chemokine production, and β-cell apoptosis. c-Met-null β-cells were more sensitive to cytokine-induced cell death in vitro, an effect mediated by NF-κB activation and NO production. Conversely, HGF treatment decreased p65/NF-κB activation and fully protected mouse and, more important, human β-cells against cytokines. CONCLUSIONS: These results show that HGF/c-Met is critical for β-cell survival by attenuating NF-κB signaling and suggest that activation of the HGF/c-Met signaling pathway represents a novel strategy for enhancing β-cell protection.

9 January 2009 in Diabetes
Verified
Journal Article
Open access
NFNathalie Fiaschi-Taesch
Nathalie Fiaschi-Taesch
TBTodd A. Bigatel
Todd A. Bigatel
BSBrian Sicari
Brian Sicari
KTKaren K. Takane
Karen K. Takane
FSFatima Salim
Fatima Salim
ASAndrew F. Stewart
Andrew F. Stewart
OBJECTIVES: To comprehensively inventory the proteins that control the G1/S cell cycle checkpoint in the human islet and compare them with those in the murine islet, to determine whether these might therapeutically enhance human β-cell replication, to determine whether human β-cell replication can be demonstrated in an in vivo model, and to enhance human β-cell function in vivo. RESEARCH DESIGN AND METHODS: Thirty-four G1/S regulatory proteins were examined in human islets. Effects of adenoviruses expressing cdk-6, cdk-4, and cyclin D1 on proliferation in human β-cells were studied in both invitro and in vivo models. RESULTS: Multiple differences between murine and human islets occur, most strikingly the presence of cdk-6 in human β-cells versus its low abundance in the murine islet. Cdk-6 and cyclin D1 in vitro led to marked activation of retinoblastoma protein phosphorylation and cell cycle progression with no induction of cell death. Human islets transduced with cdk-6 and cyclin D1 were transplanted into diabetic NOD-SCID mice and markedly outperformed native human islets in vivo, maintaining glucose control for the entire 6 weeks of the study. CONCLUSIONS: The human G1/S proteome is described for the first time. Human islets are unlike their rodent counterparts in that they contain easily measurable cdk-6. Cdk-6 overexpression, alone or in combination with cyclin D1, strikingly stimulates human β-cell replication, both in vitro as well as in vivo, without inducing cell death or loss of function. Using this model, human β-cell replication can be induced and studied in vivo.

7 May 2013 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ARAna Elena Rodriguez-Rodriguez
Ana Elena Rodriguez-Rodriguez
JTJ. Triñanes
J. Triñanes
SVS. Velazquez-Garcia
S. Velazquez-Garcia
EPEsteban Porrini
Esteban Porrini
MPM. J. Vega Prieto
M. J. Vega Prieto
ATArmando Torres
Armando Torres
Insulin resistance may interact with calcineurin inhibitors, enhancing the diabetogenic effect of tacrolimus compared with cyclosporine‐A. We studied both drugs in insulin‐resistant animals: obese Zucker rats (n = 45), and insulin‐sensitive animals: lean Zucker rats (n = 21). During 11 days, animals received saline‐buffer, cyclosporine‐A (2.5 mg/kg/day) or tacrolimus (0.3 mg/kg/day). At Days 0 and 12 animals underwent intraperitoneal glucose tolerance test (0–30–60–120 min). Islet morphometry, beta‐cell proliferation, apoptosis and Ins2 gene expression were analyzed. By Day 12, no lean animal had developed diabetes, while all obese animals on tacrolimus and 40% on cyclosporine‐A had. In obese animals, tacrolimus reduced beta‐cell proliferation and Ins2 gene expression compared with cyclosporine‐A. Five days after treatment discontinuation, partial recovery was observed, with only 10% and 60% of the animals on cyclosporine and tacrolimus remaining diabetic respectively. Beta‐cell proliferation increased in animals on tacrolimus while Ins2 gene expression remained unaltered. In conclusion, insulin resistance exacerbated the diabetogenic effect of tacrolimus compared with cyclosporine‐A. This may be explained by greater inhibition of Ins2 gene and beta‐cell proliferation by tacrolimus in the insulin resistant state. Discontinuation of the drugs may allow the recovery of the metabolic alterations.

1 January 2020 in Journal of Endocrinology
Verified
Journal Article
Closed access
CSCatalina Sierra-Ramos
Catalina Sierra-Ramos
SVSilvia Velazquez-Garcia
Silvia Velazquez-Garcia
AVArianna Vastola-Mascolo
Arianna Vastola-Mascolo
GHGuadalberto Hernández
Guadalberto Hernández
NFNourdine Faresse
Nourdine Faresse
DRDiego Alvarez de la Rosa
Diego Alvarez de la Rosa
The serum- and glucocorticoid-induced kinase 1 (SGK1) is a transcriptional target of steroid hormones including glucocorticoids or aldosterone in addition to other stimuli such as glucose. SGK1 is activated via phosphoinositide 3-kinase, placing it downstream of insulin signaling. SGK1 participates in the upregulation of kidney Na+ reabsorption by aldosterone and has been linked to obesity-related hypertension in humans. We hypothesized that a systemic increase in SGK1 activity may trigger a multiplicity of mechanisms leading to simultaneous development of the main conditions that characterize the metabolic syndrome (MetS), including hypertension. We used a transgenic mouse model made with a bacterial artificial chromosome containing the whole mouse Sgk1 gene modified to introduce an activating point mutation. Wild type or transgenic 14-week-old male mice were fed with standard chow diet or high-fat diet for up to 18 weeks. Development of the main features of MetS and hepatic steatosis were monitored, and in vitro adipocyte differentiation was studied. Our results show that transgenic animals under high-fat diet rapidly and markedly develop MetS characterized by obesity, glucose intolerance, insulin resistance, dyslipidemia and hypertension. In addition, SGK1 gain-of-function accelerates the development of hepatic steatosis. Our study suggests that inappropriate SGK1 activity represents a risk factor in developing MetS with hypertension and related end-organ damage. Our data support SGK1 as a possible therapeutic target in MetS and related complications and provides a useful gain-of-function model for pre-clinical drug testing.

16 September 2011 in Diabetes
Verified
Journal Article
Open access
PDF file
SVSilvia Velazquez-Garcia
Silvia Velazquez-Garcia
SVShelley Valle
Shelley Valle
TRTaylor C. Rosa
Taylor C. Rosa
KTKaren K. Takane
Karen K. Takane
CDCem Demirci
Cem Demirci
AGAdolfo Garcia-Ocaña
Adolfo Garcia-Ocaña
OBJECTIVE: PKC-ζ activation is a key signaling event for growth factor–induced β-cell replication in vitro. However, the effect of direct PKC-ζ activation in the β-cell in vivo is unknown. In this study, we examined the effects of PKC-ζ activation in β-cell expansion and function in vivo in mice and the mechanisms associated with these effects. RESEARCH DESIGN AND METHODS: We characterized glucose homeostasis and β-cell phenotype of transgenic (TG) mice with constitutive activation of PKC-ζ in the β-cell. We also analyzed the expression and regulation of signaling pathways, G1/S cell cycle molecules, and β-cell functional markers in TG and wild-type mouse islets. RESULTS: TG mice displayed increased plasma insulin, improved glucose tolerance, and enhanced insulin secretion with concomitant upregulation of islet insulin and glucokinase expression. In addition, TG mice displayed increased β-cell proliferation, size, and mass compared with wild-type littermates. The increase in β-cell proliferation was associated with upregulation of cyclins D1, D2, D3, and A and downregulation of p21. Phosphorylation of D-cyclins, known to initiate their rapid degradation, was reduced in TG mouse islets. Phosphorylation/inactivation of GSK-3β and phosphorylation/activation of mTOR, critical regulators of D-cyclin expression and β-cell proliferation, were enhanced in TG mouse islets, without changes in Akt phosphorylation status. Rapamycin treatment in vivo eliminated the increases in β-cell proliferation, size, and mass; the upregulation of cyclins Ds and A in TG mice; and the improvement in glucose tolerance—identifying mTOR as a novel downstream mediator of PKC-ζ–induced β-cell replication and expansion in vivo. CONCLUSIONS: PKC-ζ, through mTOR activation, modifies the expression pattern of β-cell cycle molecules leading to increased β-cell replication and mass with a concomitant enhancement in β-cell function. Approaches to enhance PKC-ζ activity may be of value as a therapeutic strategy for the treatment of diabetes.